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Abstract
Background: Cryptococcal meningitis can best be diagnosed by cerebrospinal fluid India ink microscopy, cryptococcal
antigen detection, or culture. These require invasive lumbar punctures. The utility of cryptococcal antigen detection in saliva
is unknown. We evaluated the diagnostic performance of the point-of-care cryptococcal antigen lateral flow assay (CrAg
LFA) in saliva.
Methods: We screened HIV-infected, antiretroviral therapy naı̈ve persons with symptomatic meningitis (n = 130) and
asymptomatic persons with CD4+,100 cells/mL entering into HIV care (n = 399) in Kampala, Uganda. The diagnostic
performance of testing saliva was compared to serum/plasma cryptococcal antigen as the reference standard.
Results: The saliva lateral flow assay performance was overall more sensitive in symptomatic patients (88%) than in
asymptomatic patients (27%). The specificity of saliva lateral flow assay was excellent at 97.8% in the symptomatic patients
and 100% in asymptomatic patients. The degree of accuracy of saliva in diagnosing cryptococcosis and the level of
agreement between the two sample types was better in symptomatic patients (C-statistic 92.9, k-0.82) than in
asymptomatic patients (C-statistic 63.5, k-0.41). Persons with false negative salvia CrAg tests had lower levels of peripheral
blood CrAg titers (P,0.001).
Conclusion: There was poor diagnostic performance in testing saliva for cryptococcal antigen, particularly among
asymptomatic persons screened for preemptive treatment of cryptococcosis.
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Introduction
Cryptococcal meningitis is the most common cause of adult
meningitis in Africa [1], and results in approximately 20–25% of
AIDS-related deaths. [2–4]. The majority of cases occur in sub-
Saharan Africa with an estimated 6-month survival of 20–60% [4–
6]. Availability of early initiation of antiretroviral therapy (ART) in
high-income countries has significantly reduced the burden of
cryptococcal meningitis, yet cryptococcosis continues in resource-
limited settings due to limited access to ART and failure of
retention in care [7]. Asymptomatic, subclinical cryptococcal
antigenemia precedes meningitis by weeks to months, and has
been shown to predict onset of fulminant meningitis. Cryptococcal
antigen (CrAg) prevalence rates of 4–10% in persons with CD4,
100 cells/mL worldwide [8–11], and screening for asymptomatic
antigenemia followed by subsequent preemptive antifungal ther-
apy is being undertaken in areas of high disease burden.
The new point-of-care CrAg lateral flow assay (LFA) (Immuno-
Mycologics Inc, Norman, Oklahoma) has excellent diagnostic
performance in CSF and serum, and good performance in urine
[12–14]. The LFA is stable at room temperature, has a rapid
turnaround time of 10 minutes, requires very little or no technical
skill, and can be performed with minimal laboratory infrastruc-
ture. However, the sample types, CSF and blood, that are
commonly used are obtained by invasive methods, which may be
problematic in rural, primary health centres in Africa. Hence, an
alternative sample type that is easily obtained may be of clinical
utility. We evaluated the diagnostic performance of CrAg LFA
testing of saliva compared to serum or plasma in both
symptomatic and asymptomatic patient populations in Uganda.
We sought to determine the applicability of saliva as an alternative
sample type for cryptococcal diagnostics.
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Methods
Study Design and Ethics Statement
We evaluated the diagnostic performance of saliva CrAg LFA
testing in two prospective cohorts. The first cohort included
sequential persons presenting with suspected meningitis to Mulago
National Referral Hospital in Kampala, Uganda during the
Cryptococcal Optimal ART Timing (COAT) trial (ClincalTrials.-
gov: NCT01075152) [15]. The second cohort was among those
who attended the Infectious Disease Institute (IDI) outpatient HIV
clinic between November 2011 and May 2013 as a sub-study of
the Operational Research for Cryptococcal Antigen Screening
(ORCAS) trial (ClinicalTrials.gov: NCT01535469).
Participants included in the study were $18 years, HIV-
infected, ART naı̈ve, with a CD4+ cell count ,100 cells/mL and
eligible to start ART. Those with a known history of previous
cryptococcosis or unable to provide both saliva and a blood
specimen were excluded. All research participants or their
surrogate provided written informed consent. Ethical approval
occurred from the Uganda National Council of Science and
Technology (UNCST), Mulago Hospital Research and Ethics
Committee, Makerere University Institutional Review Board, and
University of Minnesota.
Study Procedures
Symptomatic patients. Symptomatic adults presenting with
suspected meningitis on the infectious disease ward at Mulago
hospital had collection of CSF, venous blood, and saliva, after
providing informed consent. CrAg LFA was performed in real
time on saliva and either serum or plasma, depending on sample
availability. Serum and plasma were interchangeably used in this
cohort because prior validation studies we performed for the CrAg
LFA showed no difference in the two samples [12].
Asymptomatic patients. CrAg screening was implemented
among asymptomatic, ambulatory patients without signs of
cryptococcal meningitis presenting to the outpatient IDI clinic.
Patients were reviewed by a medical officer and assessed for pre-
ART CrAg screening if their CD4+,100 cell/mL (i.e. physician-
driven testing). If ART-naı̈ve, pre-ART saliva and serum CrAg
LFA test were collected prior to ART counseling. If the CrAg LFA
was positive, the patient would return to see the clinician after the
ART counseling session to review the results. In November 2012,
the system of testing in the clinic changed to lab-based reflex
testing of plasma CrAg whenever the CD4+,100 cells/mL. Any
CrAg+ patient detected by lab-based reflex testing was urgently
contacted and asked to return the next day for study consent.
Similar procedures occurred thereafter. The clinicians received
printed instructions to carefully assess the patient to rule out any
signs or symptoms of meningitis, and thereafter subjects were
consented for preemptive fluconazole therapy [16]. With lab-
based reflex CrAg testing, the time difference between plasma and
then saliva testing was 24–48 hours without any antifungal
therapy. Results of serum and plasma were pooled together for
both cohorts and hereafter referred to as serum/plasma or
reference sample.
Laboratory Analysis: Cryptococcal Antigen LFA Test
The LFA is a point-of-care lateral flow immunochromato-
graphic assay ‘‘dipstick’’ that uses gold-conjugated, anti-crypto-
coccal monoclonal antibodies impregnated onto a test strip, to
detect cryptococcal capsular polysaccharide antigen (i.e. CrAg) of
Cryptococcus neoformans and Cryptococcus gattii. The tests were
performed according to manufacturer’s instructions. Positive and
negative controls were run for every set of samples. For this
procedure, specimens were diluted 1:2 in specimen diluent. For
each sample, the test was carried out in duplicate. All laboratory
testing was performed by two trained laboratory technologists (one
for each cohort).
Statistical Analysis
Data were analyzed using STATA version 11. Analysis
established the performance of the saliva test sample in compar-
ison to the reference sample of peripheral blood (i.e. serum or
plasma). The sensitivity, specificity, positive predictive values,
negative predictive values, C-statistic, and Kappa statistic for both
populations were determined at 95% confidence interval (CI).
Results
Characteristics of the Study Population
Between November 2011 and May 2013, we screened 636
potential patients with 107 being excluded for lack of paired
samples. Among the 529 enrolled subjects assessed for cryptococ-
cal antigenemia, 130 (25%) were symptomatic and 399 (75%) were
asymptomatic (Figure 1). Both populations were similar in age
and demographics (Table 1). The median baseline CD4+ T-cell
counts among the hospitalized subjects with meningitis was 28
cells/mL (interquartile range (IQR): 7 to 70) and in the
asymptomatic outpatient subjects was 38 cells/mL (IQR: 15 to
70). Overall, 81 (15.3%) saliva specimens were CrAg positive, and
109 (20.6%) serum/plasma specimens were CrAg positive.
Diagnostic Performance of the saliva CrAg LFA Testing
In the symptomatic population with meningitis (n = 130), the
prevalence of cryptococcal antigenemia was 64% (83/130) in
serum/plasma and 57% (74/130) in saliva. There were 73 true
positives and 46 true negatives observed by the saliva LFA. Ten
subjects (8%) had a false negative saliva CrAg, and one (0.7%) had
a false positive saliva CrAg result, which was also CSF negative by
CrAg and culture.
In the asymptomatic population (n = 399), the prevalence of
cryptococcal antigenemia was 6.5% (26/399) in serum/plasma
and only 1.8% (7/399) in saliva. There were 7 true positives and
373 true negatives observed in saliva with reference to serum/
plasma. There were a substantial number of false negatives
samples (n = 19, 73%), and there were no false positives registered.
Specificity remained high as all serum/plasma CrAg negative
patients were also negative in saliva.
Using saliva, the CrAg LFA among the symptomatic population
had a sensitivity of 88% (73/83), specificity of 98% (46/47),
positive predictive value of 99% (73/74) and a negative predictive
value of 82% (46/56). The Kappa statistic (k) from the comparison
of saliva and serum/plasma among the symptomatic patients was
0.82 (P,0.001).
Among the asymptomatic population, saliva CrAg yielded a
sensitivity of only 27% (7/26), specificity of 100% (373/373),
positive predictive value of 100% (7/7) and negative predictive
value of 95% (373/392). The Kappa statistic comparing saliva and
serum/plasma among the asymptomatic patients was 0.41 (P,
0.001).
The area under the receiver-operator characteristic (ROC)
curve for sensitivity and specificity (i.e. Cstatistic) was 0.93 (95% CI:
0.888–0.970; P= 0.021) in the symptomatic population and
Cstatistic = 0.64 (95% CI: 0.547–0.721; P= 0.044) in the asymp-
tomatic population (Table 2). The inter-assay reproducibility was
good as there were no observed discordant LFAs when saliva LFAs
were tested in duplicate.
CrAg LFA Performance Using Saliva
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Saliva CrAg detectability was related to antigen burden. Among
the patients with true positive salvia LFA tests, the median
peripheral blood CrAg titer was 1:8192 (IQR, 1:1800 to .
1:64,000). In contrast, among patients with false negative saliva
CrAg testing, the median peripheral blood CrAg titer was 1:80
(IQR, 20 to 700), with a statistical difference (P,0.001).
Table 1. Characteristics of the study population.
Demographic Variable Symptomatic Meningitis Cohort Asymptomatic Outpatient Cohort
N 130 399
Women, n (%) 60 (46%) 219 (55%)
Age in years, mean (6SD) 35.7 (69.4) 35.5 (69.8)
CD4 cell count, median (IQR) cells/mL 28 (7–70) 38 (15–70)
CrAg positive in peripheral blood, n(%) 83 (64%) 26 (6.5%)
doi:10.1371/journal.pone.0103156.t001
Figure 1. The Study enrollment and Analysis populations. The figure displays the distribution of the participants tested, consisting of HIV-
infected persons from: 1) symptomatic meningitis cohort or 2) asymptomatic outpatient cohort with CD4,100 cells/mL. Saliva cryptococcal antigen
(CrAg) lateral flow assay performance was compared with the reference standard of cryptococcal antigenemia in peripheral blood (i.e. CrAg+ in serum
or plasma). The level of agreement between the two sample types is better in symptomatic patients (k= 0.82) than in asymptomatic patients
(k=0.41).
doi:10.1371/journal.pone.0103156.g001
CrAg LFA Performance Using Saliva
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Discussion
This study determined the diagnostic performance of testing
saliva for CrAg using the LFA in a real world clinical setting. The
performance of CrAg on saliva was inadequate among patients
presenting with symptomatic meningitis with an imperfect
sensitivity (88%) and positive predictive value (99%). Yet, CrAg
testing of saliva demonstrated poor sensitivity (27%) among
asymptomatic patient populations. However, the specificity and
positive predictive value remained excellent for this cohort.
When testing saliva, the LFA test strip often displayed very weak
bands suggestive of a lower antigen concentration in this sample.
In addition, there was a significant difference observed in CrAg
titers while comparing true positives verse false negatives. Patients
with false negative salvia CrAg tests had lower CrAg titers in
blood.
From a practical lab perspective, plasma was easier to work with
than serum or saliva with more rapid turnaround time. Although
the 88% sensitivity in symptomatic meningitis patients was
imperfect, the sensitivity of salvia LFA testing was higher than
that of India ink microscopy (85%) in the same cohort [12].
Although the sample size was robust, a limitation of the study is
that there was only one sole reader of the LFAs for each cohort.
The study is likely generalizable to other sub-Saharan hospitalized
and clinic populations where the burden due to cryptococcosis is
high. Although we assessed the potential for testing saliva as an
alternative sample compared to serum/plasma, the clinical utility
is not feasible. Urine or fingerstick specimens are better non-
invasive bodily fluid for testing.
In this same meningitis cohort, the CrAg LFA of urine had 97%
sensitivity (151/156) and 85% (68/80) specificity for cryptococcal
meningitis when using meningitis as the reference standard [12].
Noting, that those with a ‘‘false’’ positive urine did have
cryptococcal antigenemia in peripheral blood [12]. Similarly in a
Cape Town cohort, urine sensitivity was 98% (61/62) among
persons with a history of cryptococcal meningitis with unknown
specificity (without a control group) [13].
This study demonstrated poor diagnostic performance of saliva
CrAg LFA testing. Further diagnostic evaluation of alternative
sample types such as urine and capillary fingerstick are needed
among symptomatic and asymptomatic HIV-infected populations
in resource-limited regions. Ignoring this neglected disease will not
decrease its impact on vulnerable patients in resource-limited
settings.
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